ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2464

Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis

In Ah Choi, Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, The Republic of

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Assessment of disease activity is a key part of clinical decision in rheumatology care. High disease activity presented by disease activity score 28 ((DAS28) > 5.1 is used as a cutoff for biologic use in many countries include Korea. This study is to find confounding factors affecting erythrocyte sedimentation ratio (ESR) and C-reactive protein (CRP) to patients with rheumatoid arthritis to find the best tool to access rheumatoid arthritis (RA) disease activity, and to compare DAS28-ESR and DAS28-CRP to see whether we can use these indices interchangeably.

Methods:  A cross-sectional study was conducted in 1117 patients with RA, using initial registration data from Korean Biologics Registry (KOBIO).

Results: ESR levels were increased with age (r = 0.120, p < 0.001) and serum rheumatoid factor (r = 0.111, p = 0.001) but did not correlate with BMI, disease duration, and anti-CCP antibody titer. There were no differences in ESR levels according to the gender, smoking status, presence of diabetes mellitus, obesity (BMI ≥ 30) or low body weight (BMI < 20). CRP levels did not correlate with age, BMI, disease duration, RF and anti-CCP antibody. They were higher in female compared to male (p < 0.001) and higher in never-smoker compared to ever-smoker (p = 0.003). However, those differences of CRP levels were not significant when stratified by smoking status and gender, respectively. There were no differences in CRP levels according to the presence of diabetes mellitus, obesity (BMI ≥ 30) or low body weight (BMI < 18.5). In comparison of composite indices, DAS28CRP showed excellent correlation with DAS28ESR (r = 0.943, p < 0.001). However, in defining high disease activity, DAS28CRP showed only a fair agreement with DAS28ESR (kappa 0.381). To make best agreement with DAS28ESR in defining high disease activity, DAS28CRP need to be lowered to 4.5 (kappa 0.679, sensitivity 85.8%, specificity 88.0%, AUC 0.936).

Conclusion: DAS28CRP is a useful marker for inter-patient-comparison of RA disease activity when comparing patients with different age or rheumatoid factor status. DAS28CRP correlates well with DAS28ESR but the cutoff for high disease activity needs to be lowered to 4.5 to be used interchangeably with DAS28ESR in defining high disease activity.


Disclosure: I. A. Choi, None;

To cite this abstract in AMA style:

Choi IA. Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparison-of-disease-activity-score-das-28-crp-to-das28-esr-in-patients-with-active-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-disease-activity-score-das-28-crp-to-das28-esr-in-patients-with-active-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology